Investor Presentaiton

Current cash provides runway to reach cash flow breakeven GUARDANT™ INVESTOR 20 DAY 23 Cash Flow YE Cash >$1B Breakeven 2023 2024 2025 2026 2027 2028 <$(350m) • Five Year Total Cash Burn <$1B Therapy Selection breakeven end of 2023 Combined Therapy Selection + MRD generates positive cash flow over cumulative 5-year period • Screening ~$200m annual cash burn 153

View entire presentation